Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol
NCT ID: NCT00386282
Last Updated: 2014-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1250 participants
INTERVENTIONAL
2006-09-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus
NCT02219100
Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia
NCT02398838
A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP
NCT00386867
Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)
NCT00870272
Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation
NCT01966874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mifepristone-misoprostol treatment
200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
mifepristone-misoprostol treatment
200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mifepristone-misoprostol treatment
200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General good health
* Willingness to provide contact information for follow-up
* Absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination
Exclusion Criteria
* Intrauterine device (IUD) in place
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hector Diaz Martinez, MD
Role: PRINCIPAL_INVESTIGATOR
Clinica de Planificacion Familiar
Angela Arredondo, MD
Role: PRINCIPAL_INVESTIGATOR
Woman's Metropolitan Center
Beverly Winikoff, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Gynuity Health Projects
Gulnara Rzaeva, MD
Role: PRINCIPAL_INVESTIGATOR
Scientific Research Institute of Obstetrics & Gynecology
Besti Muradova, MD
Role: PRINCIPAL_INVESTIGATOR
Family Planning Center
Susanna Fildjyan, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Perinatology, Obstetrics and Gynecology
Armine Harutyunyan, MD
Role: PRINCIPAL_INVESTIGATOR
Center for Family Planning and Sexual Health
Anna Aghajanyan, MD
Role: PRINCIPAL_INVESTIGATOR
State Medical University
Ranulfo Rios, MD
Role: PRINCIPAL_INVESTIGATOR
H G Enrique Cabrera
Laura Garcia Martinez, MD
Role: PRINCIPAL_INVESTIGATOR
H.M.I Inguaran
Antonio E Flores, MD
Role: PRINCIPAL_INVESTIGATOR
C S Beatriz Velasco Aleman
Elba Margarita Lugo Hernandez, MD
Role: PRINCIPAL_INVESTIGATOR
C S Santa Catarina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Family Planning and Sexual Health
Yerevan, , Armenia
Institute of Perinatology, Obstetrics and Gynecology
Yerevan, , Armenia
State Medical University
Yerevan, , Armenia
Family Planning Center
Baku, , Azerbaijan
Scientific Research Institute of Obstetrics and Gynecology
Baku, , Azerbaijan
C.S. Beatriz Velasco Aleman
Mexico City, Federal District, Mexico
C.S. Santa Catarina
Mexico City, Federal District, Mexico
H.G. Enrique Cabrera
Mexico City, Federal District, Mexico
H.M.I Inguaran
Mexico City, Federal District, Mexico
Clinica de Planificacion Familiar
Lomas Verdes, Bayamon, , Puerto Rico
Woman's Metropolitan Center
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pena M, Dzuba IG, Smith PS, Mendoza LJ, Bousieguez M, Martinez ML, Polanco RR, Villalon AE, Winikoff B. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. Int J Gynaecol Obstet. 2014 Oct;127(1):82-5. doi: 10.1016/j.ijgo.2014.04.012. Epub 2014 Jun 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1.1.4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.